INVION | PoC III: COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS Melbourne (Australia) 30 May 2022: Invion Limited (ASX: IVX) is please to announce the findings from the third Proof-Of-Concept (PoC) study undertaken by its research partner, Hudson Institute of Medical Research (Hudson Institute). The PoC was specifically designed to evaluate whether INV043 can be used in…
Read more
Cho Group Chairman wins defamation suit against uSpiked editor
CHO GROUP | PRESS RELEASE Cho Group Chairman wins defamation suit against uSpiked editor Queensland court finds gossip website editor-in-chief defamed Michael Cho Defendant ordered to pay $350,000 in damages to Mr Cho Court issued an injunction restraining the defendant from publishing or republishing the defamatory articles or articles with similar content Melbourne, Australia –…
Read more
Legal action against Mr Mark Thomas
Defamation action against the editor of gossip website has commenced Law firm Jones Day has been appointed as solicitors for Michael Honsue Cho Defendant has failed to lodge defence as required by law Default judgement application has been filed against the defendant The court action relates to three defamatory articles authored by the defendant Melbourne,…
Read more
Invion Collaborates to Develop Powerful Skin Cancer Gel
Invion moves to develop more effective skin cancer gel The gel is a topical formulation of IVX-P02, an improved version of Photosoft™ technology, which is being developed as a treatment for cancers Human clinical trials targeted to commence in 201 Experts Formulytica and vivoPharm engaged for development and testing of skin cancer gel Melbourne, Australia,…
Read more